Cipla is setting up a new 60:40 joint venture with Kemwell Biopharma in India.

This strategic move involves an initial partner investment of up to INR 10 Cr into the new company, with Cipla investing INR 6 Cr for its 60% stake.

The JV will focus on developing, manufacturing, and commercializing biologic products for global markets.

This collaboration leverages Kemwell's strong biologics CDMO expertise and US FDA-certified facilities, significantly enhancing Cipla's product portfolio and manufacturing capabilities in the fast-growing biopharmaceutical sector.